Log in to save to my catalogue

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_176925

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

About this item

Full title

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2020-06, Vol.382 (23), p.2197-2206

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Among men with high-risk, nonmetastatic, castration-resistant prostate cancer, the addition of enzalutamide to androgen-deprivation therapy improved overall survival by nearly a year as compared with ADT alone: median survival was 67 months with enzalutamide plus ADT and 56 months with ADT alone.

Alternative Titles

Full title

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_umu_176925

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_176925

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2003892

How to access this item